Showing results (471-480 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|February 1, 2017
The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side EffectsLiang Ding, Jing Ren, Dongya Zhang, et al.
Molecular Cancer Therapeutics|February 1, 2017
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer CellsHo-June Lee, Yi Cao, Victoria Pham, et al.
Molecular Cancer Therapeutics|February 1, 2017
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal MelanomaHanyin Cheng, Vivian Chua, Connie Liao, et al.
Molecular Cancer Therapeutics|February 15, 2017
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPARAntonella Borgatti, Joseph S Koopmeiners, Aaron L Sarver, et al.
Molecular Cancer Therapeutics|February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide LinkersThomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.
Molecular Cancer Therapeutics|January 26, 2017
In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and ResistanceAbu Syed Md Anisuzzaman, Abedul Haque, Dongsheng Wang, et al.
Molecular Cancer Therapeutics|January 11, 2017
MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2Peilong Li, Xin Zhang, Haiyan Wang, et al.
Molecular Cancer Therapeutics|March 16, 2019
δ-Catenin Promotes Bevacizumab-Induced Glioma InvasionToshihiko Shimizu, Joji Ishida, Kazuhiko Kurozumi, et al.
Molecular Cancer Therapeutics|March 16, 2019
TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719XKimihiro Ito, Makoto Nishio, Masanori Kato, et al.
Molecular Cancer Therapeutics|February 15, 2014
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemiaKathleen Keegan, Cong Li, Zhihong Li, et al.
Pageof 599